CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

Adenocaine solutions from CAPS arrive prelabeled with CAPS high-contrast labeling to maximize legibility and usability in the operating room, and with tamper evidence for added safety.

"When it comes to high-quality service, CAPS delivers. That means Adenocaine users will now have reliable, convenient and consistent access to our solutions whenever they need them," said David C. Field, Chief Executive Officer for Hibernation Therapeutics. "State-of-the-art cleanroom technology and more than 15 years of experience in the cardioplegia solution market make CAPS the ideal provider of Adenocaine preparations."

CAPS offers the industry's widest range of service options, including same day and next day delivery, 365 days a year.

"We're excited to offer this unique, proprietary, patented solution and service to the cardioplegia market," said Todd Jones, Director of Marketing for CAPS. "Our quality focus and high level of service will complement the innovative solutions from Hibernation Therapeutics."

CAPS meets or exceeds USP Chapter <797> guidelines to safely deliver high-quality admixtures to hospitals from coast to coast.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 20). CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia. News-Medical. Retrieved on December 05, 2024 from https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx.

  • MLA

    B. Braun Melsungen AG. "CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia". News-Medical. 05 December 2024. <https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx>.

  • Chicago

    B. Braun Melsungen AG. "CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia". News-Medical. https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx. (accessed December 05, 2024).

  • Harvard

    B. Braun Melsungen AG. 2019. CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia. News-Medical, viewed 05 December 2024, https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021